Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 1
A Phase I Trial of TOR-582, a Topical Sirolimus-based Treatment for Epistaxis in Adults With Hereditary Hemorrhagic Telangiectasia
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical…
Hereditary Hemorrhagic Telangiectasia (HHT)Epistaxis
Estimated
~$10 – $6,250
Columbia UniversityNCT07667413
Phase 1
InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN-6400 in Adult Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in…
Hereditary Hemorrhagic Telangiectasia
Estimated
~$10 – $8,750
Alnylam PharmaceuticalsNCT06659640
CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiect…
Hereditary Hemorrhagic TelangiectasiaArteriovenous MalformationsTelangiectasia+4 more
Estimated
~$10 – $1,125
Cure HHTNCT06259292